Búsqueda | Biblioteca Virtual en Salud

1.

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Lisberg, A; Cummings, A; Goldman, J W; Bornazyan, K; Reese, N; Wang, T; Coluzzi, P; Ledezma, B; Mendenhall, M; Hunt, J; Wolf, B; Jones, B; Madrigal, J; Horton, J; Spiegel, M; Carroll, J; Gukasyan, J; Williams, T; Sauer, L; Wells, C; Hardy, A; Linares, P; Lim, C; Ma, L; Adame, C; Garon, Edward B.

J Thorac Oncol ; 13(8): 1138-1145, 2018 08.

Artículo en Inglés | MEDLINE | ID: mdl-29874546

2.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

Cancer Res ; 58(13): 2793-800, 1998 Jul 01.

Artículo en Inglés | MEDLINE | ID: mdl-9661893

3.

An institutional commitment to pain management.

Ferrell, B R; Dean, G E; Grant, M; Coluzzi, P.

J Clin Oncol ; 13(9): 2158-65, 1995 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-7666074

4.

Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers.

Coluzzi, P H; Grant, M; Doroshow, J H; Rhiner, M; Ferrell, B; Rivera, L.

J Clin Oncol ; 13(3): 756-64, 1995 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-7533828

5.

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.

Christie, J M; Simmonds, M; Patt, R; Coluzzi, P; Busch, M A; Nordbrock, E; Portenoy, R K.

J Clin Oncol ; 16(10): 3238-45, 1998 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9779697

6.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

Morgan, R J; Doroshow, J H; Venkataraman, K; Chang, K; Raschko, J; Somlo, G; Leong, L; Tetef, M; Shibata, S; Hamasaki, V; Margolin, K; Forman, S; Akman, S; Coluzzi, P; Ahn, C; Weiss, L; Gadgil, U; Harrison, J.

Clin Cancer Res ; 3(12 Pt 1): 2337-45, 1997 Dec.

Artículo en Inglés | MEDLINE | ID: mdl-9815632

7.

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Portenoy, R K; Payne, R; Coluzzi, P; Raschko, J W; Lyss, A; Busch, M A; Frigerio, V; Ingham, J; Loseth, D B; Nordbrock, E; Rhiner, M.

Pain ; 79(2-3): 303-12, 1999 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-10068176

8.

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Coluzzi, P H; Schwartzberg, L; Conroy, J D; Charapata, S; Gay, M; Busch, M A; Chavez, J; Ashley, J; Lebo, D; McCracken, M; Portenoy, R K.

Pain ; 91(1-2): 123-30, 2001 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-11240084

9.

Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial.

Tetef, M; Margolin, K; Ahn, C; Akman, S; Chow, W; Coluzzi, P; Leong, L; Morgan, R J; Raschko, J; Shibata, S.

J Cancer Res Clin Oncol ; 121(2): 103-6, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-7883772

10.

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.

Raschko, J W; Synold, T W; Chow, W; Coluzzi, P; Hamasaki, V; Leong, L A; Margolin, K A; Morgan, R J; Shibata, S I; Somlo, G; Tetef, M L; Yen, Y; ter Veer, A; Doroshow, J H.

Cancer Chemother Pharmacol ; 46(5): 403-10, 2000.

Artículo en Inglés | MEDLINE | ID: mdl-11127945

11.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.

Newman, E M; Carroll, M; Akman, S A; Chow, W; Coluzzi, P; Hamasaki, V; Leong, L A; Margolin, K A; Morgan, R J; Raschko, J W; Shibata, S; Somlo, G; Tetef, M; Yen, Y; Ahn, C W; Doroshow, J H.

Cancer Chemother Pharmacol ; 39(3): 254-8, 1997.

Artículo en Inglés | MEDLINE | ID: mdl-8996529

12.

Sublingual morphine: efficacy reviewed.

Coluzzi, P H.

J Pain Symptom Manage ; 16(3): 184-92, 1998 Sep.

Artículo en Inglés | MEDLINE | ID: mdl-9769621

13.

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.

Payne, R; Coluzzi, P; Hart, L; Simmonds, M; Lyss, A; Rauck, R; Berris, R; Busch, M A; Nordbrook, E; Loseth, D B; Portenoy, R K.

J Pain Symptom Manage ; 22(1): 575-83, 2001 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-11516599

14.

Survey of analgesic use for nonmalignant pain in long-term care facilities in southern California.

Fujimoto, D; Coluzzi, P H.

J Am Med Dir Assoc ; 1(3): 109-13, 2000.

Artículo en Inglés | MEDLINE | ID: mdl-12818022

15.

Cancer pain management: newer perspectives on opioids and episodic pain.

Coluzzi, P H.

Am J Hosp Palliat Care ; 15(1): 13-22, 1998.

Artículo en Inglés | MEDLINE | ID: mdl-9468974

16.

Oral patient-controlled analgesia.

Coluzzi, P H.

Semin Oncol ; 24(5 Suppl 16): S16-35-42, 1997 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9381226

17.

Hospital--creating a pain-free environment: a program to improve pain control in hospitalized patients.

Coluzzi, P.

J Palliat Care ; 9(2): 50, 1993.

Artículo en Inglés | MEDLINE | ID: mdl-8377073

18.

The management of pain in terminally ill cancer patients with difficulty swallowing.

Coluzzi, P H; Fairbairn, B S.

Am J Hosp Palliat Care ; 16(6): 731-7, 1999.

Artículo en Inglés | MEDLINE | ID: mdl-11094910

19.

Managing breakthrough pain. New method expands treatment options.

Rhiner, M; Coluzzi, P H.

Adv Nurse Pract ; 6(1): 41-3, 68, 1998 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-9495944

20.

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.

Tetef, M; Doroshow, J; Akman, S; Coluzzi, P; Leong, L; Margolin, K; Morgan, R J; Raschko, J; Shibata, S; Somlo, G.

Cancer Invest ; 13(5): 460-3, 1995.

Artículo en Inglés | MEDLINE | ID: mdl-7552810

Biblioteca Virtual en Salud

Hipertensión

Su selección (0)

Formato de exportación:

Exportar:

A Phase II Study of Pembrolizumab in EGFR-Mutant, PD-L1+, Tyrosine Kinase Inhibitor Naïve Patients With Advanced NSCLC.

Phase I trial of intraperitoneal iododeoxyuridine with and without intravenous high-dose folinic acid in the treatment of advanced malignancies primarily confined to the peritoneal cavity: flow cytometric and pharmacokinetic analysis.

An institutional commitment to pain management.

Survey of the provision of supportive care services at National Cancer Institute-designated cancer centers.

Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain.

High-dose infusional doxorubicin and cyclophosphamide: a feasibility study of tandem high-dose chemotherapy cycles without stem cell support.

Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled dose titration study.

Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR).

Mitomycin C and menadione for the treatment of advanced gastrointestinal cancers: a phase II trial.

A phase I study of carboplatin and etoposide administered in conjunction with dipyridamole, prochlorperazine and cyclosporine A.

Pharmacokinetics and toxicity of 120-hour continuous-infusion hydroxyurea in patients with advanced solid tumors.

Sublingual morphine: efficacy reviewed.

Long-term safety of oral transmucosal fentanyl citrate for breakthrough cancer pain.

Survey of analgesic use for nonmalignant pain in long-term care facilities in southern California.

Cancer pain management: newer perspectives on opioids and episodic pain.

Oral patient-controlled analgesia.

Hospital--creating a pain-free environment: a program to improve pain control in hospitalized patients.

The management of pain in terminally ill cancer patients with difficulty swallowing.

Managing breakthrough pain. New method expands treatment options.

5-Fluorouracil and high-dose calcium leucovorin for hepatocellular carcinoma: a phase II trial.